

Cardiac Disease Screening – Lipid Profile

Date of Origin: 04/2003

Last Review Date: 01/22/2020

Effective Date: 02/01/2020

Dates Reviewed: 01/2004, 04/2005, 12/2005, 06/2006, 06/2007, 07/2008, 6/2011, 05/2012, 03/2013, 07/2014, 09/2015, 09/2016, 08/2017, 02/2019, 01/2020

Developed By: Medical Necessity Criteria Committee

I. Description

The traditional risk factors for cardiovascular disease include smoking, hypertension, diabetes, obesity, age, family history, lipid abnormalities and sedentary lifestyle. Nearly half of the patients that present with a myocardial infarction do not have these classic risk factors. This finding has directed research to look for other risk factors that may be responsible for coronary artery disease and to develop screening tests to predict future coronary events in healthy individuals. Cholesterol screening consisting of a lipid profile which includes total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, and triglycerides are covered for members with coverage for preventative services. Several nontraditional markers of cardiovascular risk have been developed to improve identification of patients at high risk. These include the following laboratory tests:

High Sensitivity C-reactive protein (hs-CRP): (CPT 86141) It is thought that certain markers of inflammation may indicate the development of atherosclerosis. High sensitivity C-reactive protein is a systemic marker of inflammation that has been used as a screening test for assessing cardiovascular disease risk.

Homocysteine: (CPT 83090) is an amino acid normally found in the body. Studies suggest that high blood levels of homocysteine may increase an individual's chance of developing heart disease, stroke and damage to arteries.

Apolipoprotein A-I, LDL gradient gel electrophoresis, and Lipoprotein (a) immunoassay: (CPT 82172, 83695) these tests are performed to help determine coronary heart disease risk and to guide drug and diet therapy in patients with established coronary artery disease.

Apolipoprotein B: is thought to be a useful risk assessment tool in patients with normal LDL who have a high family risk for premature coronary artery disease. However, apo B assays have not been fully standardized and there is no consensus on predictive or treatment value. Apolipoprotein E polymorphisms have functional effects on lipoprotein metabolism and have been studied in disorders associated with elevated cholesterol levels and lipid derangements. Research investigators have found

that the apo E genotype yields poor predictive values when screening for clinically defined atherosclerosis.

LDL subspecies: Larger and smaller low-density lipoprotein (LDL) particle size may be associated with coronary heart disease. In addition, nearly half of patients with coronary atherosclerotic disease have dense LDL particles. When present, dense LDL greatly increases the risk of coronary disease.

HDL subspecies: High-density lipoprotein (HDL) is known as the “good cholesterol”, however, not all HDL is beneficial. HDL subfractions (lipoprotein AI (LpAI) and lipoprotein AI/AII (LpAI/AII) and/or HDL3 and HDL2) have also been used for risk prediction. However, studies have not shown superiority of HDL subspecies over HDL cholesterol in CHD risk assessments.

Angiotensin gene (AGT) or CardiaRisk: This test analyzes angiotensin gene polymorphisms which have been associated with cardiovascular disease risk and some forms of hypertension. Certain AGT polymorphisms have been associated with responsiveness of blood pressure to ACE inhibitor therapy and sodium reduction. Therefore, analysis of the AGT gene may be beneficial in helping to predict how patients will respond to certain antihypertensive interventions. CardiaRisk is a lab test done at Myriad Genetics Laboratories that analyzes the angiotensinogen gene.

II. Criteria: CWQI HCS-0015

- A. Moda Health covers the following tests for preventive cholesterol screening when the member has benefits available: total cholesterol, high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), VLDL (very low density lipoprotein), and triglycerides.
- B. Moda Health will cover hs-CRP as a medical diagnostic only. hs-CRP is considered investigational and will not be covered when performed as a routine screening test.
- C. Moda Health will cover Homocysteine testing (measurements of plasma homocysteine) for **1 or more of the following**:
 - a. Assessment of borderline vitamin B12 deficiency, where the results will impact the member’s management
 - b. Assessment of homocysteinuria caused by cystathionine beta synthase deficiency (Note: for newborn screening, measurements of plasma homocysteine/total homocysteine are performed only when hypermethioninemia has been confirmed)
 - c. Assessment of idiopathic venous thrombo-embolism
 - d. Assessment of recurrent venous thrombo-embolism
 - e. Assessment of thrombosis occurring at a young age (i.e. less than 45 years of age)
 - f. Assessment of thrombosis at an unusual site
 - g. Moda Health considers homocysteine testing experimental or investigational for all other indications
- D. Moda Health will allow limited coverage of specific tests under the following circumstances for **1 or more of the following**:
 - a. Lipoprotein (a) and hs-CRP will be covered for young individuals who have unexplained coronary artery disease and lack traditional risk factors.

- b. Lipoprotein (a) will be covered for members with the diagnosis of complex lipid disorder with familial hyperlipidemia, such as Familial Lp (a) hyperlipidemia.
- E. Apolipoprotein B will be covered for members undergoing management of lipoprotein abnormalities **and** who have **1 or more** of the following:
 - a. Diabetes; or
 - b. Coronary heart disease; or
 - c. Member is a smoker; or
 - d. Member has a family history of premature coronary heart disease
- F. Other laboratory tests for assessing coronary heart disease are considered investigational for screening, diagnosing, or managing coronary heart disease.

III. Information Submitted with the Prior Authorization Request

1. Documentation from the ordering physician supporting one of the above listed indications.
2. When performed as a routine screening, these tests are considered investigational and will not be covered. Prevailing medical literature does not support the use of these tests for screening of coronary heart disease.

IV. CPT or HCPC codes covered

Codes	Description
80061	Lipid panel
82172	Apolipoprotein, each
82465	Cholesterol, serum or whole blood, total
83695	Lipoprotein (a)
83718	Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol)
83721	Lipoprotein, direct measurement; LDL cholesterol
84478	Triglycerides
86141	C-reactive protein, high sensitivity (hsCRP)
83090	Homocysteine

V. CPT or HCPC codes not covered

Codes	Description
83704	Lipoprotein, blood; quantitation of lipoprotein particle numbers and lipoprotein particle subclasses

VI. Annual Review History

Review Date	Revisions	Effective Date
03/2013	Annual Review: Added table with review date, revisions, and effective date.	04/03/2013
06/2014	Annual Review: No change	06/2014
9/2015	Removed ICD-9 codes, added ICD-10	9/26/2015
9/2016	Annual Review: Minor change – added age for Apolipoprotein B.	9/28/2016
08/2017	Annual Review: Included itemized list of codes approved for Homocysteine	08/23/2017
02/27/2019	Annual Review: Include criteria for homocysteine testing	03/01/2019
01/22/2020	Annual Review: Codes updated	02/01/2020

VII. References

1. Clarke R, Peden JF, Hopewell JC, et al; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. *N Engl J Med.* 2009;361(26):2518-2528.
2. Contois JH, McConnell JP, Sethi AA, et al.; AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Apolipoprotein B and cardiovascular disease risk: Position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. *Clin Chem.* 2009;55(3):407-419.
3. Cooper GR, Wilson PWF, Myers GL, et al. Lipoprotein (a) and cardiovascular disease risk. In: *Emerging biomarkers for primary prevention of cardiovascular disease and stroke. Laboratory Medicine Practice Guidelines.* G. Meyers, ed. Product ID 5660. Washington, DC: National Academy of Clinical Biochemistry; 2009
4. C-reactive protein as a predictor for atherosclerotic progression and recurrent cardiac events. *Hayes Alert.* January 2005; 8(1):3-4.
5. Danesh J, Wheeler J, Hirschfield G, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *The New England Journal of Medicine.* April 2004; 350(14):1387-1397.
6. Does C-reactive protein predict cardiovascular risk better than LDL? *Hayes Alert;* Dec. 2002; 5(12).
7. Durga J, van Tits L, Schouten E, et al. Effect of lowering of homocysteine levels on inflammatory markers: A randomized controlled trial. *Arch Intern Med.* June 27, 2005; 165:1388-1394.
8. Emerging Risk Factors Collaboration; Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. *Lancet.* 2010;375(9709):132-140.
9. Grundy, et al. *AHA/ACC Scientific statement: assessment of cardiovascular risk by use of multiple-risk-factor assessment equations.* *J. American College of Cardiology.* 1999; 34:1348-59.
10. Guthrie RM. Counseling patients about lipid management. Part 1. What are the goals of therapy? *Medical World Communications.* May 2003.
11. Lp-PLA(2) Studies Collaboration; Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies. *Lancet.* 2010; 375(9725):1536-1544.

12. McQueen MJ, Hawken S, Wang X, et al.; INTERHEART study investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): A case-control study. *Lancet*. 2008; 372(9634):224-233.
13. Nontraditional markers of cardiovascular risk. *Diabetes Forum*. 2002; 1(2).
14. Pai J, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. *The New England Journal of Medicine*. December 2004; 351(25):2599-2610.
15. Pearson TA, et al. Markers of inflammation and cardiovascular disease. American Heart Association 2003.
16. Ridker P, Hennekens C, Buring J. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *The New England Journal of Medicine*. March 2000; 342:836-843.
17. Risk Factors for Atherosclerotic Disease, *A Textbook of Cardiovascular Medicine*, 6th ed., 2001, Ch. 31.
18. U.S. Preventive Services Task Force (USPSTF). Using nontraditional risk factors in coronary heart disease risk assessment. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); October 2009. Assessed on May 18, 2011 at: <http://www.ahrq.gov/clinic/uspstf/uspstfcoronaryhd.htm>
19. Physician Advisors

Appendix 1 – Applicable ICD-10 codes approved for Homocysteine test

Codes	Description
D51.0-D51.9	Vitamin B12 deficiency anemia
D81.818	Other biotin-dependent carboxylase deficiency
D81.819	Biotin-dependent carboxylase deficiency, unspecified
E53.8	Deficiency of other specified group B vitamins
E72.10 - E72.11; E72.19	Disturbances of Sulphur-bearing amino-acid metabolism (not covered for management of 5, 10-methylenetetrahydrofolate reductase [MTHFR] abnormalities)
I26.01 – I26.99	Pulmonary embolism
I81	Portal vein thrombosis
I82.0 – I82.91	Other venous embolism and thrombosis
T81.718D	Embolism of cardiac prosthetic devices, implants and grafts, sequelae
T82.818D	Embolism of vascular prosthetic devices, implants and grafts, subsequent encounter
T82.817A	Embolism of cardiac prosthetic devices, implants and grafts, initial encounter
I74.01	Saddle embolus of abdominal aorta
I74.19	Embolism and thrombosis of other parts of aorta
I74.10	Embolism and thrombosis of unspecified parts of aorta
I74.09	Other arterial embolism and thrombosis of abdominal aorta
I74.11	Embolism and thrombosis of thoracic aorta
I74.2	Embolism and thrombosis of arteries of the upper extremities
I74.4	Embolism and thrombosis of arteries of extremities, unspecified
I74.3	Embolism and thrombosis of arteries of the lower extremities
I74.5	Embolism and thrombosis of iliac artery
I74.8	Embolism and thrombosis of other arteries
I74.9	Embolism and thrombosis of unspecified artery

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD):

Jurisdiction(s): 5, 8	NCD/LCD Document (s):

NCD/LCD Document (s):

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC